NRx Pharmaceuticals, Inc.
NRXP
$2.21
-$0.085-3.71%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.00% | -28.11% | -36.62% | -44.55% | -47.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.58% | -38.08% | -36.10% | -36.55% | -37.77% |
| Operating Income | 28.58% | 38.08% | 36.10% | 36.55% | 37.77% |
| Income Before Tax | 16.66% | 43.48% | 36.49% | 31.35% | 24.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.66% | 43.48% | 36.49% | 31.35% | 24.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.66% | 43.48% | 36.49% | 31.35% | 24.16% |
| EBIT | 28.58% | 38.08% | 36.10% | 36.55% | 37.77% |
| EBITDA | 28.58% | 38.09% | 36.10% | 36.56% | 37.78% |
| EPS Basic | 42.43% | 57.64% | 51.97% | 43.07% | 32.11% |
| Normalized Basic EPS | 38.94% | 50.90% | 49.10% | 46.86% | 44.84% |
| EPS Diluted | 42.70% | 57.80% | 52.13% | 42.72% | 31.79% |
| Normalized Diluted EPS | 38.94% | 50.90% | 49.10% | 46.86% | 44.84% |
| Average Basic Shares Outstanding | 40.88% | 33.33% | 30.71% | 22.36% | 15.26% |
| Average Diluted Shares Outstanding | 40.88% | 33.33% | 30.71% | 22.36% | 15.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |